{
    "clinical_study": {
        "@rank": "92524", 
        "acronym": "PROTECT", 
        "arm_group": [
            {
                "arm_group_label": "Tacrolimus plus Everolimus", 
                "arm_group_type": "Experimental", 
                "description": "Low dose Tacrolimus + Everolimus"
            }, 
            {
                "arm_group_label": "Tacrolimus plus Mycophenolic acid", 
                "arm_group_type": "Active Comparator", 
                "description": "standard dose Tacrolimus + Mycophenolic acid"
            }
        ], 
        "brief_summary": {
            "textblock": "To evaluate prevention effect of combination therapy of Everolimus and low-dose Tacrolimus\n      in comparison with standard-dose Tacrolimus therapy with Mycophenolic acid on the New Onset\n      Diabetes Mellitus after transplantation in the renal allograft recipients"
        }, 
        "brief_title": "Evaluate Efficacy Study of Combination Therapy of Everolimus and Low Dose Tacrolimus in Renal Allograft Recipients", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Kidney; Complications, Allograft", 
        "detailed_description": {
            "textblock": "An open-label, randomized, multi-center, comparative parallel study to evaluate prevention\n      effect of combination therapy of Everolimus and low-dose Tacrolimus in comparison with\n      standard-dose Tacrolimus therapy with Mycophenolic acid on the New Onset Diabetes Mellitus\n      after transplantation in the renal allograft recipients: PROTECT study"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Age \u2265 20 year old\n\n          2. At least 3 months after kidney transplantation\n\n          3. Subject who is using Tacrolimus \u00b1 purine synthesis inhibitor + steroid without change\n             within the past 3 months (except the dosage)\n\n          4. MDRD eGFR \u2265 50 mL/min or serum creatinine < 2.0mg/dL within the past 3 months in the\n             6months after kidney transplantation\n\n          5. Rate of change of serum creatinine < +30% within the past 3 months in the 6months\n             after kidney transplantation (if serum creatinine decreased, without rate of change\n             is inclusion possible. if serum creatinine result was normal,regardless of the rate\n             of change is able to register.)\n\n          6. Urine protein/creatinine ratio < 1g/g Cr (spot urine) Subject who is not applicable\n             to the diagnostic criteria NODAT on\n\n          7. the baseline in the 6months after kidney transplantation\n\n          8. Subjects who agree with written informed consent\n\n        Exclusion Criteria:\n\n          1. Subjects who received combined non-renal transplantation\n\n          2. Subject who received re-transplantation\n\n          3. ABO blood group incompatible(when anti-ABO Antibody titer <1:128 is inclusion\n             possible.)\n\n          4. Sensitized patients before transplantation\n\n               -  Pretransplant or peak PRA titer > 50%\n\n               -  Pretransplant T cell cytotoxicity crossmatch (+)\n\n          5. HLA-identical living related donor\n\n          6. Subject who has diabetes mellitus / NODAT before transplantation\n\n          7. Subject who has suffered acute rejection episode within the past 3 months in the\n             6months after kidney transplantation\n\n          8. Subject with hypersensitivity to everolimus\n\n          9. Subject who should continue nephrotoxic drug until enrollment (Aminoglycoside,\n             amphotericin B, cisplatin)\n\n         10. Subject with GI disorder that might interfere with the ability to absorb oral\n             medication. (eg, gastrectomy or insufficiently treated diabetic gastroenteropathy)\n\n         11. Subjects with active peptic ulcer\n\n         12. HIV, HBsAg, or HCV Ab tests (+)\n\n         13. Abnormal liver function test (AST or ALT or total bilirubin> upper normal limit x3)\n\n         14. ANC <1.5*109/L or WBC <2.5*109/L or platelet <75*109/L\n\n         15. Treatment with an investigational drug within 30 days preceding the first dose of\n             trial medication\n\n         16. Women who are either pregnant, lactating, planning to become pregnant in the next 12\n             months.\n\n         17. Subjects with history of cancer(except successfully treated), localized\n             nonmelanocytic skin cancer, PTLD(Post-transplant lymphoproliferative disorder)\n\n         18. Subjects with clinically significant infections within the past 4 weeks in the\n             6months after kidney transplantation\n\n         19. Subjects who took major surgery within the past 4 weeks in the 6months after kidney\n             transplantation"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "234", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02036554", 
            "org_study_id": "CRAD001AKR11T"
        }, 
        "intervention": [
            {
                "arm_group_label": "Tacrolimus plus Everolimus", 
                "description": "Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.", 
                "intervention_name": "Everolimus", 
                "intervention_type": "Drug", 
                "other_name": "Certican"
            }, 
            {
                "arm_group_label": [
                    "Tacrolimus plus Everolimus", 
                    "Tacrolimus plus Mycophenolic acid"
                ], 
                "description": "Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.", 
                "intervention_name": "Tacrolimus", 
                "intervention_type": "Drug", 
                "other_name": "Tacroli"
            }, 
            {
                "arm_group_label": "Tacrolimus plus Mycophenolic acid", 
                "description": "Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.", 
                "intervention_name": "Mycophenolic acid", 
                "intervention_type": "Drug", 
                "other_name": "Cellcept"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Mycophenolic Acid", 
                "Sirolimus", 
                "Mycophenolate mofetil", 
                "Everolimus", 
                "Tacrolimus"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "January 13, 2014", 
        "location": {
            "contact": {
                "email": "yangch@catholic.ac.kr", 
                "last_name": "Chul Woo Yang", 
                "phone": "82-2-2258-6851"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "division of nephrology;Seoul St Mary's Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "To Evaluate Prevention Effect Of Everolimus and Low-dose Tacrolimus in Comparison With Standard-dose Tacrolimus Therapy With Mycophenolic Acid on the New Onset Diabetes Mellitus After Transplantation in the Renal Allograft Recipients", 
        "overall_official": {
            "affiliation": "St Mary's Hospital, London", 
            "last_name": "Chul-Woo Yang, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "To evaluate prevention effect of combination therapy of Everolimus and low-dose Tacrolimus in comparison with standard-dose Tacrolimus therapy with Mycophenolic acid on the New Onset Diabetes Mellitus after transplantation at 12 months after date of randomization.", 
            "measure": "Change from Baseline in Development of NODAT (Fasting glucose \u2265 126 mg/dL, Random glucose \u2265 200 mg/dL) at 12 months", 
            "safety_issue": "No", 
            "time_frame": "0 to 12 month"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02036554"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Seoul St. Mary's Hospital", 
            "investigator_full_name": "ChulWoo Yang", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "Change from Baseline(V2) in Insulin resistance by HOMA-IR at 12months(V6)", 
                "measure": "Insulin resistance by HOMA-IR", 
                "safety_issue": "No", 
                "time_frame": "0 to 12 months"
            }, 
            {
                "description": "Change from Baseline(V2) in insulin secretion by HOMA-beta at 12 months(V6)", 
                "measure": "Insulin secretion by HOMA-beta", 
                "safety_issue": "No", 
                "time_frame": "0 to 12 months"
            }, 
            {
                "description": "Change from baseline in OGTT (Fasting and PP2hr) at 12 months(V6)", 
                "measure": "OGTT (Fasting and PP2hr)", 
                "safety_issue": "No", 
                "time_frame": "0 to 12 months"
            }, 
            {
                "description": "Needs for anti-diabetic medication or insulin at Baseline(V2)", 
                "measure": "Needs for anti-diabetic medication or insulin", 
                "safety_issue": "No", 
                "time_frame": "at Baseline(V2)"
            }, 
            {
                "description": "Needs for anti-diabetic medication or insulin at 3 month(V3)", 
                "measure": "Needs for anti-diabetic medication or insulin at 3 month(V3)", 
                "safety_issue": "No", 
                "time_frame": "at 3 month(V3)"
            }, 
            {
                "description": "Needs for anti-diabetic medication or insulin at 6 month(V4)", 
                "measure": "Needs for anti-diabetic medication or insulin at 6 month(V4)", 
                "safety_issue": "No", 
                "time_frame": "at 6 month(V4)"
            }, 
            {
                "description": "Needs for anti-diabetic medication or insulin at 9 month(V5)", 
                "measure": "Needs for anti-diabetic medication or insulin at 9 month(V5)", 
                "safety_issue": "No", 
                "time_frame": "at 9 month(V5)"
            }, 
            {
                "description": "Needs for anti-diabetic medication or insulin at 12 month(V6)", 
                "measure": "Needs for anti-diabetic medication or insulin at 12 month(V6)", 
                "safety_issue": "No", 
                "time_frame": "at 12 month(V6)"
            }, 
            {
                "description": "Creatinine clearance (MDRD eGFR) at Baseline(V2)", 
                "measure": "Creatinine clearance (MDRD eGFR) at Baseline(V2)", 
                "safety_issue": "No", 
                "time_frame": "at Baseline(V2)"
            }, 
            {
                "description": "Creatinine clearance (MDRD eGFR) at 3 month(V3)", 
                "measure": "Creatinine clearance (MDRD eGFR) at 3 month(V3)", 
                "safety_issue": "No", 
                "time_frame": "at 3 month(V3)"
            }, 
            {
                "description": "Creatinine clearance (MDRD eGFR) at 6 month(V4)", 
                "measure": "Creatinine clearance (MDRD eGFR) at 6 month(V4)", 
                "safety_issue": "No", 
                "time_frame": "at 6 month(V4)"
            }, 
            {
                "description": "Creatinine clearance (MDRD eGFR) at 9 month(V5)", 
                "measure": "Creatinine clearance (MDRD eGFR) at 9 month(V5)", 
                "safety_issue": "No", 
                "time_frame": "at 9 month(V5)"
            }, 
            {
                "description": "Creatinine clearance (MDRD eGFR) at 12 month(V6)", 
                "measure": "Creatinine clearance (MDRD eGFR) at 12 month(V6)", 
                "safety_issue": "No", 
                "time_frame": "at 12 month(V6)"
            }, 
            {
                "description": "After date of randomization, evaluate graft survival rate at 12 months(V6)", 
                "measure": "12 month graft survival", 
                "safety_issue": "No", 
                "time_frame": "at 12 months(V6)"
            }, 
            {
                "description": "After date of randomization, evaluate patient survival rate at 12 months(V6)", 
                "measure": "12 month patient survival rate", 
                "safety_issue": "No", 
                "time_frame": "at 12 months(V6)"
            }, 
            {
                "description": "Change from baseline in Microalbuminuria(MAU) at 12 months", 
                "measure": "Change from baseline in Microalbuminuria(MAU) at 12 months", 
                "safety_issue": "No", 
                "time_frame": "at 12 months(V6)"
            }, 
            {
                "description": "Proportion of patients with significant proteinuria greater than 1g/gCr at Baseline(V2)", 
                "measure": "Proportion of patients with significant proteinuria greater than 1g/gCr at Baseline(V2)", 
                "safety_issue": "No", 
                "time_frame": "at Baseline(V2)"
            }, 
            {
                "description": "Proportion of patients with significant proteinuria greater than 1g/gCr at 3 month(V3)", 
                "measure": "Proportion of patients with significant proteinuria greater than 1g/gCr at 3 month(V3)", 
                "safety_issue": "No", 
                "time_frame": "at 3 month(V3)"
            }, 
            {
                "description": "Proportion of patients with significant proteinuria greater than 1g/gCr at 6 month(V4)", 
                "measure": "Proportion of patients with significant proteinuria greater than 1g/gCr at 6 month(V4)", 
                "safety_issue": "No", 
                "time_frame": "at 6 month(V4)"
            }, 
            {
                "description": "Proportion of patients with significant proteinuria greater than 1g/gCr at 9 month(V5)", 
                "measure": "Proportion of patients with significant proteinuria greater than 1g/gCr at 9 month(V5)", 
                "safety_issue": "No", 
                "time_frame": "at 9 month(V5)"
            }, 
            {
                "description": "Proportion of patients with significant proteinuria greater than 1g/gCr at 12 month(V6)", 
                "measure": "Proportion of patients with significant proteinuria greater than 1g/gCr at 12 month(V6)", 
                "safety_issue": "No", 
                "time_frame": "at 12 month(V6)"
            }, 
            {
                "description": "Cumulative incidence rate of Biopsy Proven Acute Rejection(BPAR) at 12months(V6) after date of randomization.", 
                "measure": "Number of episode of biopsy proven acute rejection (BPAR)", 
                "safety_issue": "No", 
                "time_frame": "at 12 month(V6)"
            }, 
            {
                "description": "Number of hospitalization of any cause (except admission for protocol biopsy) at Baseline(V2)", 
                "measure": "Number of hospitalization of any cause (except admission for protocol biopsy) at Baseline(V2)", 
                "safety_issue": "No", 
                "time_frame": "at Baseline(V2)"
            }, 
            {
                "description": "Number of hospitalization of any cause (except admission for protocol biopsy) at 3 month(V3)", 
                "measure": "Number of hospitalization of any cause (except admission for protocol biopsy) at 3 month(V3)", 
                "safety_issue": "No", 
                "time_frame": "at 3 month(V3)"
            }, 
            {
                "description": "Number of hospitalization of any cause (except admission for protocol biopsy) at 6 month(V4)", 
                "measure": "Number of hospitalization of any cause (except admission for protocol biopsy) at 6 month(V4)", 
                "safety_issue": "No", 
                "time_frame": "at 6 month(V4)"
            }, 
            {
                "description": "Number of hospitalization of any cause (except admission for protocol biopsy) at 9 month(V5)", 
                "measure": "Number of hospitalization of any cause (except admission for protocol biopsy) at 9 month(V5)", 
                "safety_issue": "No", 
                "time_frame": "at 9 month(V5)"
            }, 
            {
                "description": "Number of hospitalization of any cause (except admission for protocol biopsy) at 12 month(V6)", 
                "measure": "Number of hospitalization of any cause (except admission for protocol biopsy) at 12 month(V6)", 
                "safety_issue": "No", 
                "time_frame": "at 12 month(V6)"
            }, 
            {
                "description": "Number of opportunistic infections (BKVN) at Baseline(V2)", 
                "measure": "Number of opportunistic infections (BKVN) at Baseline(V2)", 
                "safety_issue": "No", 
                "time_frame": "at Baseline(V2)"
            }, 
            {
                "description": "Number of opportunistic infections (BKVN) at 12month(V6)", 
                "measure": "Number of opportunistic infections (BKVN) at 12month(V6)", 
                "safety_issue": "No", 
                "time_frame": "at 12 month(V6)"
            }, 
            {
                "description": "Prevalence of NODAT at Baseline(V2)", 
                "measure": "Prevalence of NODAT at Baseline(V2)", 
                "safety_issue": "No", 
                "time_frame": "at Baseline(V2)"
            }, 
            {
                "description": "Prevalence of NODAT at 3 month(V3)", 
                "measure": "Prevalence of NODAT at 3 month(V3)", 
                "safety_issue": "No", 
                "time_frame": "at 3 month(V3)"
            }, 
            {
                "description": "Prevalence of NODAT at 6 month(V4)", 
                "measure": "Prevalence of NODAT at 6 month(V4)", 
                "safety_issue": "No", 
                "time_frame": "at 6 month(V4)"
            }, 
            {
                "description": "Prevalence of NODAT at 9 month (V5)", 
                "measure": "Prevalence of NODAT at 9 month (V5)", 
                "safety_issue": "No", 
                "time_frame": "at 9 month (V5)"
            }, 
            {
                "description": "Prevalence of NODAT at 12 month(V6)", 
                "measure": "Prevalence of NODAT at 12 month(V6)", 
                "safety_issue": "No", 
                "time_frame": "at 12 month(V6)"
            }
        ], 
        "source": "Seoul St. Mary's Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Novartis", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Seoul St. Mary's Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}